Perrigo Company plc (NYSE:PRGO) Receives Consensus Recommendation of “Hold” from Brokerages

Perrigo Company plc (NYSE:PRGO) has earned an average rating of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $19.3333.

PRGO has been the topic of a number of research reports. Canaccord Genuity Group dropped their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Finally, Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th.

Perrigo Trading Down 2.3%

NYSE:PRGO opened at $10.60 on Friday. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. Perrigo has a 12 month low of $9.23 and a 12 month high of $28.43. The company has a market cap of $1.47 billion, a PE ratio of -0.81, a price-to-earnings-growth ratio of 1.27 and a beta of 0.52. The company has a 50 day simple moving average of $10.77 and a two-hundred day simple moving average of $13.20.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company’s revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Research analysts forecast that Perrigo will post 2.14 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be issued a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 10.9%. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Institutional Investors Weigh In On Perrigo

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. grew its position in shares of Perrigo by 291.9% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after purchasing an additional 5,828,076 shares in the last quarter. Norges Bank purchased a new position in shares of Perrigo during the fourth quarter valued at about $42,607,000. Invesco Ltd. grew its position in shares of Perrigo by 134.2% during the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after purchasing an additional 2,602,724 shares in the last quarter. ION Fund Management Ltd purchased a new position in shares of Perrigo during the fourth quarter valued at about $24,499,000. Finally, Vanguard Group Inc. grew its position in shares of Perrigo by 7.9% during the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after purchasing an additional 1,101,154 shares in the last quarter. 95.91% of the stock is owned by institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.